109:110-117.
Warwick-Brown NP, Cheesman AD. Intracranial metastases from a supraglottic carcinoma. The Journal of Laryngology and Otology. 2010; 101:624-626.
Bakshi J, Verma RK, Chakraborty S, Sarvanan K. Isolated intracranial metastases from an early glottis cancer: How rare apresentation? Ind J Otolaryngol Head and Neck Surg 2010; 61(1):62-65.
Martínez Subías JJ, Lahoz Zamarro T, Laguía Pérez M, Valero Ruiz FJ Cámara Jiménez F. Our experience in carcinoma of larynx with brain metastases Hospital General ¨Obispo Polanco¨ de Teruel. Servicio de Otorrinolaringología O.R.L. ARAGON 2001; 4(2):10-13.
Cartwright RA, Watkins G. Epidemiology of Hodgkin’s disease: a review. Hematol Oncol. 2004; 22:11-26.
Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008; 19:379-390.
Olson JE, Janney CA, Rao RD. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002; 95:1504-1510.
Pulido JS, Robert A, Vierkant JE, Lauren Abrey O, David Schiff and O’Neill BP. Racial differences in primary central nervous system lymphoma incidence and survival rates Neuro-Oncology 11(3): 318-322.
Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin’s lymphoma: a review of the literature. Semin Neurol 2004; 24(4):395–404.
SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow up analysis of SWOG 8516 — the Southwest Oncology Group. J Clin Oncol 2009; 27(1):114–119.
Bex GS, Sonke FJ, Pos D, Brandsma JM, Kerst S. Horenblas Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Annals of Oncology 2010; 21:2240–2245.
Siefker-Radtke AO, Dinney CP,Abrahams NA. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder:a retrospective review of the M.D. Anderson cancer experience. J Urol 2004; 172: 481–484.
Lester JF, Hudson E, Barber JB. Bladder preservation in small cell carcinoma of the urinary bladder: an institutional experience and review of the literature. Clin Oncol (R Coll Radiol) 2006; 18:608–611.
Cancer Metastases: Duration between Cancer Onset and Lung Metastasis as an Important Prognostic Factor. Ann. Surg. Oncol. 2009; 16:1026–1032.
Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, PiccartGebhart MJ. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 2010; 75(2):110–121.
Suh JH: Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 2010; 362:1119-1127.
Delattre JY, Krol G, Thaler HT, Posner JB: Distribution of brain metastases. Arch Neurol 1988; 45:741-744.
Ameer L.E., Mackay A.R., Wayne T .Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients Elaimy et al. World Journal of Surgical Oncology 2011, 9:69 .
Alessandra Fabi, Alessandra Felici, Giulio Metro, Alessandra Mirri, Emilio Bria, Stefano Telera, Luca Moscetti, Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. Journal of Experimental & Clinical Cancer Research 2011; 30:10.
Narayana A, Recht L, Gutin PH. Central nervous system tumors. In: Hoppe, RT, Philips, TL, Roach, M (3rd Ed.), Textbook of Radiation Oncology. Philadelphia, PA: Saunders; 2010:421–432.
Eileen P. Connolly, Maya Mathew, Moses Tam, Josephine Vera King. Involved field radiation therapy after surgical resection of solitary brain metastases—mature results. Neuro-Oncology 2013; 15(5):589–594.
Timothy C, Ryken Michael, McDermott, Robinson PD. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:103–114.
Centre for Evidence-Based Physiotherapy Physiotherapy evidence database (PEDro).[en linia] Disponible . http://www.pedro.org.au/.
Robinson PD, Kalkanis SN, Linskey ME, Santaguida PL. Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol. 2009.
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI (2009) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Bio lPhys 43(4):795–803.
Tallett AV, Azria S, Barlesi F, Spano JP, Carpentier AF, Goncalves A and Metellus P (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment Radiat Oncol 28:7–77.
Patel AJ, Suki D, Hatiboglu MA, Abouassi H, Shi W, Wildrick DM, Lang FF and Sawaya R Factors influencing the risk of local recurrence after resection of a single brain metastasis J Neurosurg 2010;113(2)181–9. Kamp M A, Dibué M, Santacroce A. The tumour is not enough or is it? Problems and new concepts in the surgery of cerebral metastases. Cancer 2013; 7:306.
Roberge D, Parney IF and Brown PD Radiosurgery to the Postoperative Surgical Cavity: Who Needs Evidence? Int J Radiation Oncol Biol Phys 2011; 83(2):486 -93.
Brem SS, Bierman PJ, Brem H. NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers. JNCCN–Journal of the National Comprehensive Cancer Network 2011; 9(4); 352-400.
Soffietti R, Cornu P, Delattre JY. Brain metastases. En: Gilhus NE, Barnes MP, Brainin M (Ed), European Handbook of Neurological Management 2001; 1(2nd Edition): 437-445.
Siena S, Crino LL, Danova M. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study Annals of Oncology 2010; 21:655–661.
Agarwala SS, Kirkwood JM, Gore M. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22:2101–2107.
Shimato S, Mitsudomi T, Kosaka T. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncology. 2006; 8:137–44.
Porta R, Sánchez-Torres JM, Paz-Ares L. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011; 37:624-31.
Andrews DW, Scott CB, Sperduto PW. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III